Sexual dysfunction in men taking systemic dermatologic medication: A systematic review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 30905792.
- Also identified by DOI 10.1016/j.jaad.2019.03.043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prescription medications are among the most common causes of sexual dysfunction, and patients are often hesitant to seek help when experiencing these symptoms. In this review, we identify the available evidence of sexual adverse effects in men using systemic dermatologic medications and suggest screening protocols and actions that may improve a patient's symptoms where possible. A systematic review was conducted of all articles in the PubMed database published from the time of inception to May 2018 to identify studies evaluating the use of systemic dermatologic medications in men with evidence of sexual adverse effects. Subsequently, a secondary in-depth literature review was performed for each individual medication. There were 5497 articles reviewed in the primary systematic review, and 59 articles covering 11 systemic dermatologic medications met inclusion criteria. We identified level 1 evidence for sexual adverse effects as a primary outcome in patients taking finasteride. Many included studies were limited by sample size and methodology. The information in this review may serve as a reference of adverse effects when deciding on a therapeutic agent and a guide to help identify patients to screen for sexual dysfunction.
Medical subject headings
- Adrenal Cortex Hormones
- Dermatologic Agents
- Finasteride
- Itraconazole
- Sexual Dysfunction, Physiological